<DOC>
	<DOCNO>NCT01340300</DOCNO>
	<brief_summary>Metformin medication commonly use treatment diabetes . Recently small study cancer patient without diabetes suggest metformin may benefit lower insulin level . In study patient cancer diabetes , glucose ( sugar ) level blood generally lower . Insulin insulin-like growth factor affect growth cancer cell . This randomized study compare different intervention ; exercise , exercise metformin , metformin alone , control arm . The investigator directly test either exercise metformin affect disease . The investigator test affect insulin level body well blood marker . The investigator believe blood test may either related cancer recurrence early sign cancer recurrence test exercise metformin may change marker .</brief_summary>
	<brief_title>Exercise Metformin Colorectal Breast Cancer Survivors</brief_title>
	<detailed_description>Subjects randomize one four group : exercise training , exercise training metformin , metformin alone , control arm . All subject lifestyle measurement , interview regard activity level , diet questionnaire , blood test . Subjects randomize exercise training participate two supervised exercise session per week exercise physiologist 3 month . They also ask exercise additional 120 minute week . Subjects randomize exercise training metformin participate two supervised exercise session per week take metformin . Metformin take daily first two week twice daily 3 month . Subjects randomize metformin take metformin daily first two week twice daily . Subjects control arm receive packet educational information nutrition physical activity develop National Cancer Institute American Cancer Society . In addition education information , offer two supervised session exercise physiologist well pedometer 3 month enrollment study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Histologically confirm stage IIII colorectal breast cancer Undergone curativeintent complete surgical resection complete adjuvant therapy ( indicate ) least 2 month prior enrollment Note : Breast cancer subject hormonal therapy trastuzumab therapy colorectal cancer subject adjunctive therapy consider cytotoxic chemotherapy ( include participate CALGB 80702 receive celocoxib/placebo ) eligible . Participants allow receive concomitant adjuvant endocrine therapy breast cancer ; however , endocrine agent must initiate least 1 month prior enrollment study continue throughout duration study participation . Less 120 minute exercise per week Approval oncologist surgeon English speaking able read English No plan surgery anticipate 3 month intervention period At least one month major surgery start intervention include colostomy reversal Concurrent malignancy history malignancy treat within past 3 year ( nonmelanoma skin cancer insitu cervical cancer ) Metastatic disease Scheduled receive form adjuvant cancer therapy Currently medication diabetes treatment Pregnant breastfeed Any condition associate increase risk metforminassociated lactic acidosis ( prior renal failure liver failure , history acidosis type ; habitual intake 3 alcoholic beverage per day ) Known hypersensitivity intolerance metformin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Colorectal</keyword>
	<keyword>Breast</keyword>
	<keyword>Insulin</keyword>
	<keyword>Exercise</keyword>
</DOC>